- Home
- BREA vs EVAX Comparison
BREA vs EVAX Comparison
Compare BREA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- EVAX
- Stock Information
- Founded
- BREA 2022
- EVAX 2008
- Country
- BREA Ireland
- EVAX Denmark
- Employees
- BREA N/A
- EVAX N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BREA Consumer Discretionary
- EVAX Health Care
- Exchange
- BREA Nasdaq
- EVAX Nasdaq
- Market Cap
- BREA 14.8M
- EVAX 17.8M
- IPO Year
- BREA 2023
- EVAX 2021
- Fundamental
- Price
- BREA $7.65
- EVAX $2.93
- Analyst Decision
- BREA
- EVAX Strong Buy
- Analyst Count
- BREA 0
- EVAX 2
- Target Price
- BREA N/A
- EVAX $10.00
- AVG Volume (30 Days)
- BREA 234.0K
- EVAX 68.5K
- Earning Date
- BREA 01-01-0001
- EVAX 10-30-2025
- Dividend Yield
- BREA N/A
- EVAX N/A
- EPS Growth
- BREA N/A
- EVAX N/A
- EPS
- BREA N/A
- EVAX N/A
- Revenue
- BREA $2,988,009.00
- EVAX $3,176,000.00
- Revenue This Year
- BREA N/A
- EVAX N/A
- Revenue Next Year
- BREA N/A
- EVAX $425.50
- P/E Ratio
- BREA N/A
- EVAX N/A
- Revenue Growth
- BREA 151.51
- EVAX 1042.45
- 52 Week Low
- BREA $5.00
- EVAX $1.20
- 52 Week High
- BREA $19.50
- EVAX $16.69
- Technical
- Relative Strength Index (RSI)
- BREA 63.71
- EVAX 51.89
- Support Level
- BREA $5.87
- EVAX $2.81
- Resistance Level
- BREA $14.84
- EVAX $3.04
- Average True Range (ATR)
- BREA 0.96
- EVAX 0.21
- MACD
- BREA 0.19
- EVAX -0.00
- Stochastic Oscillator
- BREA 21.25
- EVAX 68.64
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.